Investment Summary

Oxford Brain Diagnostics is the result of an 8-year collaboration between Professor Steven Chance (neuroscience and pathology) and Professor Mark Jenkinson (brain imaging), and has resulted in the development of the Cortical Disarray Measurement (CDM), a novel approach that uses MRI scans to provide an index of the health of the cellular circuits in patients’ brains. CDM gives quantitative results to detect whether the patient is likely to develop dementia or not.

This platform technology will initially be applied to the diagnosis of Alzheimer’s disease and has the potential to be used to identify other brain conditions as the company grows and expands into new markets.